Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Hospital Practice

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3810/hp.2011.02.369PMID 21441754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vildagliptin

  2012cited by this paper
• American Association of Clinical Endocrinologists

  2011cited by this paper
• Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

  2011cited by this paper
• Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

  2010cited by this paper
• The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

  2010cited by this paper
• Association of Diabetes, Comorbidities, and A1C With Functional Disability in Older Adults

  2010cited by this paper
• Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study

  2010cited by this paper
• Sitagliptin

  2010cited by this paper
• Alogliptin

  2010cited by this paper
• Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16

  2010cited by this paper
• Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

  2010cited by this paper
• Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors

  2010cited by this paper
• Metformin and cancer: licence to heal?

  2010cited by this paper
• Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

  2010cited by this paper
• Saxagliptin in type 2 diabetes.

  2010cited by this paper
• The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study

  2010cited by this paper
• Saxagliptin for type 2 diabetes

  2010cited by this paper
• A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

  2010cited by this paper
• Type 2 diabetes and risk for functional decline and disability in older persons.

  2010cited by this paper
• Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

  2010cited by this paper
• Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy

  2010cited by this paper
• Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

  2010cited by this paper
• Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

  2009cited by this paper
• American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control

  2009cited by this paper
• Varying insulin use in older hospitalized patients with diabetes

  2009cited by this paper
• Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes

  2009cited by this paper
• Antidiabetic Oral Treatment in Older People

  2009influential reference
• Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus.

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes

  2009cited by this paper
• Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.

  2009cited by this paper
• Neurocognitive impairment and comorbid depression in patients of diabetes mellitus

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Glitazone use associated with diabetic macular edema.

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Key priorities in managing glucose control in older people with diabetes

  2009cited by this paper
• Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

  2009cited by this paper
• Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24‐week, double‐blind, randomized trial

  2009cited by this paper
• Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

  2009cited by this paper
• P89 Quel est le lien entre l’équilibre glycémique et la morbi-mortalité à 5 ans de diabétiques de type 2 de 70 ans et plus : projet GERODIAB

  2009cited by this paper
• Liraglutide

  2009cited by this paper
• Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

  2009cited by this paper
• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

  2009cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009cited by this paper
• New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly

  2008influential reference
• Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus *

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Complications DOI: 10.1111/j.1464-5491.2009.02667.x Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor

  2008cited by this paper
• Hypoglycaemia in Type 2 diabetes

  2008cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real‐Life Effectiveness and Care Patterns of Diabetes Management (RECAP‐DM) Study

  2008cited by this paper
• Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia *

  2008cited by this paper
• The growing burden of diabetes mellitus in the US elderly population.

  2008cited by this paper
• Evidence that vildagliptin attenuates deterioration of glycaemic control during 2‐year treatment of patients with type 2 diabetes and mild hyperglycaemia *

  2008cited by this paper
• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

  2008cited by this paper
• The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

  2007cited by this paper
• Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP‐4 inhibitors

  2007influential reference
• Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes

  2007cited by this paper
• Severe hypoglycemia in critically ill patients: Risk factors and outcomes*

  2007cited by this paper
• Management of Type 2 Diabetes in Treatment-Naive Elderly Patients

  2007cited by this paper
• Disability and quality of life in elderly people with diabetes.

  2007cited by this paper
• Severe iatrogenic hypoglycemia in type 2 diabetes mellitus

  2007cited by this paper
• A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education.

  2007cited by this paper
• Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

  2007cited by this paper
• Establishing pragmatic estimated GFR thresholds to guide metformin prescribing

  2007cited by this paper
• A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

  2007cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Thiazolidinedione use and bone loss in older diabetic adults.

  2006cited by this paper
• Improving metabolic control leads to better working memory in adults with type 2 diabetes.

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care.

  2005cited by this paper
• Contraindications can damage your health—is metformin a case in point?

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes.

  2005cited by this paper
• Hypoglycaemia in elderly diabetic patients.

  2005cited by this paper
• Use of antidiabetic drugs in elderly patients.

  2005cited by this paper
• Caring the elderly diabetic patient with respect to concepts of successful aging and frailty.

  2005cited by this paper
• Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Hypoglycaemia in Elderly Patients with Diabetes Mellitus

  2004cited by this paper
• Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

  2003cited by this paper
• Acarbose in the treatment of elderly patients with type 2 diabetes.

  2003cited by this paper
• Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

  2002cited by this paper
• Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

  2001cited by this paper
• Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study.

  2001cited by this paper
• Mortality in older people with diabetes mellitus

  1997cited by this paper
• ONE HUNDRED YEARS AGO

  1995cited by this paper
• A Population‐based Study of the Incidence of Complications Associated with Type 2 Diabetes in the Elderly

  1991cited by this paper

• A Comprehensive Review of the Effects of Glycemic Carbohydrates on the Neurocognitive Functions Based on Gut Microenvironment Regulation and Glycemic Fluctuation Control

  2023cites this paper
• Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis

  2022cites this paper
• Effects of Glucagon-like Peptide-1 Analogues and Dipeptidyl Peptidase-IV Inhibitors on Hepatic Oxidative Stress and Non-Alcoholic Steatohepatitis in Male Albino Rats

  2020cites this paper
• Diabetes Management in Older Adults With Chronic Kidney Disease

  2019cites this paper
• Biomarkers associated with glycaemic control, comorbidity and response to GLP-1 analogue therapy

  2018cites this paper
• A novel fibroblast growth factor 1 variant reverses nonalcoholic fatty liver disease in type 2 diabetes.

  2018cites this paper
• STUDY OF RISK ABERRANT OF TYPE-2 DIABETES - CURRENT APPROACHES FOR CARE AND CONTROL.

  2016cites this paper
• [Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors].

  2016cites this paper
• Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study

  2015cites this paper
• Hoofdstuk 9 (Farmaco)therapie van diabetes mellitus type 2 bij de oudere patiënt

  2015cites this paper
• Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  2015cites this paper
• Dipeptidyl peptidase‐4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes

  2015cites this paper
• Hoofdstuk 13 De obese diabetespatiënt op oudere leeftijd

  2015cites this paper
• Prise en charge pragmatique du diabétique en EHPAD

  2014cites this paper
• Optimal therapy of type 2 diabetes: a controversial challenge

  2014cites this paper
• Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention

  2014cites this paper
• Diabetes mellitus and kidney disease in the elderly.

  2014cites this paper
• The older patient with diabetes: a practical approach

  2014cites this paper
• Étude HYPOCRAS : comparaison en vie réelle chez des patients âgés diabétiques de type 2 d’un traitement par inhibiteur de la DPP-4 versus autres antidiabétiques oraux en ajout à la metformine

  2014cites this paper
• Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials Bradley H. CurtisTina M. ReesKim A. Gaskins • Justo Sierra-JohnsonRong LiuHonghua H. Jiang •

  2014cites this paper
• Diabetes mellitus y enfermedad renal en el anciano

  2014cites this paper
• Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study

  2014cites this paper
• Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.

  2013cites this paper
• Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin

  2013cites this paper
• Pragmatic diabetes management in nursing homes: individual care plan.

  2013cites this paper
• Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

  2013influential citation
• Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.

  2013cites this paper
• Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials

  2013cites this paper
• Inhibitory DPP-4 u osób starszych – bezpieczeństwo i skuteczność w jednym?

  2013cites this paper
• Management of Type 2 Diabetes Mellitus in Older Patients: Current and Emerging Treatment Options

  2013cites this paper
• Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial

  2013cites this paper
• Elderly Patients With Type 2 Diabetes Mellitus-the Need for High-Quality, Inpatient Diabetes Care

  2013cites this paper
• Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis

  2013cites this paper
• Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

  2013cites this paper
• Management of Type 2 Diabetes Mellitus in Older Adults

  2012cites this paper
• Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

  2012cites this paper
• A review of gliptins in 2011

  2012cites this paper
• Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

  2012cites this paper
• Managing Diabetes in Patients With Diabetes of Long Duration

  2012cites this paper
• Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting

  2012cites this paper
• Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

  2012cites this paper
• Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study.

  2012cites this paper
• Insulin Use in Elderly Adults: Risk of Hypoglycemia and Strategies for Care

  2012cites this paper
• Incretin Therapies in the Management of Patients with Type 2 Diabetes Mellitus and Renal Impairment

  2012cites this paper
• GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

  2012cites this paper
• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  2012cites this paper
• Management of type 2 diabetes mellitus in the elderly.

  2011cites this paper
• Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review.

  2011cites this paper
• Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

  2010cites this paper